Dupixent Q1 Sales Hit $3.66 Billion, Up Over 20% Year-over-Year, as New Indication Expands Market Potential

Apr 24, 2025 17:29 CST Updated 17:29

Sanofi

Pharmaceutical R&D Developer

On April 24, Sanofi released its Q1 2025 financial report,Dupixent(Dupilumab)Sales reached$3.66 billion（EUR 3.48 billion, EUR/USD Q1 average exchange rate=1.0518）, an increase of 20.3% year-on-year(Calculated at constant exchange rates CER, same below)。Including U.S. market revenue$2.6 billion（EUR 2.476 billion), an increase of 18.4% year-on-year.

Screenshot source: Corporate earnings report

Dupixent is a fully human monoclonal antibody jointly developed by Sanofi and Regeneron, which inhibits signaling in the IL-4 and IL-13 pathways. The drug is currentlyMarketed in China, the United States, the European Union, Japan, and other countries and regions, with approved indications includingAtopic Dermatitis, Asthma, Chronic RhinosinusitisWith Nasal Polyps, Eosinophilic Esophagitis, Nodular PrurigoAndChronic Obstructive Pulmonary Diseaseetc.

Screenshot source: Insight database

Since its first approval for marketing in 2017,Dupixent Sales have been rising steadily. In 2023, the drug first entered the billion-dollar molecule club, with total sales for 2024Achieve13.072 billion euros, a year-on-year increase of 23.1%, becomingFollowingAdalimumab in the futureThe Next Generation of Autoimmune "Blockbuster Drug"。

Screenshot source: Insight database

Notably, just last week, Regeneron and Sanofi announced that the FDA hadApproval Dupixent A new indication has been approved for marketing in China, intended for the treatment of children aged 12 years and older and adults whose condition is not well controlled with H1 antihistamines.Chronic Spontaneous Urticaria（CSU）. Thus far,Dupixent's indications have been further expanded, and its market potential has been further tapped.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor：ccai

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn